Drug intelligence / Profile preview

HighOsmo

Development stage: Preclinical
Lead developer: Umeå University
Modality: Small Molecules
Administration: Intravenous

Overview

HighOsmo is a trial-specific, hyperosmolar cardiopulmonary-bypass priming solution evaluated by Umeå University for its potential effect on postoperative acute kidney injury in patients undergoing cardiac surgery. The 966 mOsm formulation used in the HighOsmo arm contains Ringer-acetate, mannitol, sodium chloride, and heparin. It is administered through the cardiopulmonary-bypass circuit; mannitol and added sodium chloride raise prime osmolality, while heparin provides anticoagulation during extracorporeal circulation. ([ctv.veeva.com](https://ctv.veeva.com/study/hyperosmolality-and-acute-kidney-injury-after-cardiac-surgery))

Other names: high-osmolality priming solutionhyperosmolar priming solution

Targets

ATIII (Antithrombin III)

Beyond the preview

Go deeper on HighOsmo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HighOsmo.

Explore the full profile